Results from an interim analysis in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients remain on track for 4Q 2025Expect to ...
During the call as well as in our slide presentation and supplemental Excel file, we reference certain non-GAAP financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback